True Wealth Design LLC Has $42,000 Stock Holdings in 10x Genomics $TXG

True Wealth Design LLC grew its stake in shares of 10x Genomics (NASDAQ:TXG) by 1,552.5% in the second quarter, according to the company in its most recent filing with the SEC. The firm owned 3,586 shares of the company’s stock after acquiring an additional 3,369 shares during the quarter. True Wealth Design LLC’s holdings in 10x Genomics were worth $42,000 as of its most recent SEC filing.

A number of other hedge funds also recently modified their holdings of TXG. GAMMA Investing LLC lifted its position in 10x Genomics by 81.8% during the first quarter. GAMMA Investing LLC now owns 3,586 shares of the company’s stock worth $31,000 after purchasing an additional 1,614 shares during the period. Signaturefd LLC raised its position in shares of 10x Genomics by 134.3% in the 1st quarter. Signaturefd LLC now owns 4,203 shares of the company’s stock valued at $37,000 after buying an additional 2,409 shares in the last quarter. Whittier Trust Co. acquired a new position in shares of 10x Genomics in the 1st quarter valued at approximately $41,000. PNC Financial Services Group Inc. boosted its position in shares of 10x Genomics by 153.6% during the 1st quarter. PNC Financial Services Group Inc. now owns 5,150 shares of the company’s stock worth $45,000 after acquiring an additional 3,119 shares in the last quarter. Finally, US Bancorp DE boosted its position in shares of 10x Genomics by 314.5% during the 1st quarter. US Bancorp DE now owns 5,973 shares of the company’s stock worth $52,000 after acquiring an additional 4,532 shares in the last quarter. Institutional investors own 84.68% of the company’s stock.

10x Genomics Stock Up 17.3%

Shares of TXG stock opened at $15.25 on Friday. 10x Genomics has a twelve month low of $6.78 and a twelve month high of $17.25. The stock’s fifty day simple moving average is $12.81 and its 200 day simple moving average is $11.77. The firm has a market capitalization of $1.90 billion, a P/E ratio of -24.60 and a beta of 2.13.

10x Genomics (NASDAQ:TXG) last posted its earnings results on Thursday, November 6th. The company reported ($0.22) EPS for the quarter, beating the consensus estimate of ($0.27) by $0.05. The firm had revenue of $149.00 million during the quarter, compared to the consensus estimate of $142.50 million. 10x Genomics had a negative return on equity of 11.71% and a negative net margin of 11.89%.The business’s quarterly revenue was down 1.7% on a year-over-year basis. During the same period last year, the company earned ($0.30) earnings per share. 10x Genomics has set its Q4 2025 guidance at EPS. As a group, equities research analysts expect that 10x Genomics will post -1.43 EPS for the current fiscal year.

Insider Activity at 10x Genomics

In related news, insider Benjamin J. Hindson sold 7,486 shares of 10x Genomics stock in a transaction that occurred on Friday, August 22nd. The shares were sold at an average price of $13.79, for a total transaction of $103,231.94. Following the sale, the insider directly owned 440,888 shares in the company, valued at $6,079,845.52. This trade represents a 1.67% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Adam Taich sold 22,315 shares of the business’s stock in a transaction that occurred on Friday, August 22nd. The stock was sold at an average price of $13.79, for a total transaction of $307,723.85. Following the sale, the chief financial officer directly owned 309,273 shares in the company, valued at $4,264,874.67. The trade was a 6.73% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 39,149 shares of company stock worth $539,865 in the last quarter. 9.39% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

Several research analysts have commented on TXG shares. UBS Group boosted their price objective on shares of 10x Genomics from $13.00 to $14.00 and gave the company a “neutral” rating in a research report on Friday. Wall Street Zen upgraded 10x Genomics from a “hold” rating to a “buy” rating in a research report on Friday, October 3rd. Canaccord Genuity Group raised their price objective on 10x Genomics from $16.00 to $19.00 and gave the company a “buy” rating in a research note on Friday. JPMorgan Chase & Co. boosted their target price on 10x Genomics from $13.00 to $15.00 and gave the stock a “neutral” rating in a research note on Friday. Finally, Deutsche Bank Aktiengesellschaft set a $14.00 target price on shares of 10x Genomics and gave the stock a “hold” rating in a report on Friday, August 8th. One equities research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, seven have issued a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat, 10x Genomics presently has an average rating of “Hold” and a consensus price target of $14.58.

10x Genomics Profile

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.